Trade Gilead GILD

Gilead live chart

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

Gilead News

Sophia Claire 2025 Oct 25, 00:00

September CPI Inflation Data and Federal Reserve Outlook: An Analysis

Emma Rose 2025 Oct 25, 00:00

JPMorgan: Stock Market Likely to Shrug Off High CPI Data Amid Fed Rate Cut Hopes

Frances Wang 2025 Oct 23, 16:00

Gold price outlook: gold price dips to $4,095, what’s next for XAU/USD?

commodity
Frances Wang 2025 Oct 23, 16:00

Bitcoin rises above $111K: What’s driving Bitcoin (BTC/USD) prices?

crypto
Frances Wang 2025 Oct 22, 16:00

Nvidia (NVDA) Stock Prediction: What $NVDA Will be Worth at the End of 2026?

stocks
Frances Wang 2024 Aug 04, 16:00

The Week Ahead: ISM services, SMCI

CFD Trading
Magnificent Seven earnings take centre stage in the markets this week
Neil Wilson 2024 Apr 19, 01:00

Week ahead: Wall Street’s Magnificent Seven earnings are up

Commodities Forex Indices Shares
Disney is catching up with Netflix
Neil Wilson 2024 Feb 01, 08:03

Week ahead: Earnings season climax

Forex Indices
Consumer inflation
Neil Wilson 2023 Nov 03, 04:01

Week ahead: RBA poised to hike?

Forex Indices
Megacap-tech-stocks.jpg
Neil Wilson 2023 Apr 21, 05:00

Week ahead: Megacap tech and 1-in-3 Dow components set to report

Latest news

Show more
Ava Grace 2025 Oct 25, 00:00

Trump's Sudden Russia Policy Shift: Rubio's Influence and Implications

Emma Rose 2025 Oct 25, 00:00

Global Market Review: Gold Volatility and Tech Stock Surge Amidst Economic Uncertainty

Noah Lee 2025 Oct 25, 00:00

September CPI Data: Inflation Hurdles, Tariff Impacts, and Fed Rate Cut Expectations

Emma Rose 2025 Oct 25, 00:00

Navigating the AI Boom: Strategies for Investors Amid Nvidia's Valuation Surge

Sophia Claire 2025 Oct 25, 00:00

Fund Managers Cautious in Q4: AI, Inflation, and Monetary Policy in Focus

Emma Rose 2025 Oct 25, 00:00

US Government Shutdown Threatens October Inflation Data Release

Sophia Claire 2025 Oct 24, 00:00

US-EU Relations: Russia Sanctions Unite Despite Trade Tensions

Emma Rose 2025 Oct 24, 00:00

BOJ Warns of Japan Stock Market Overheating, U.S. Trade Policy Risk

Info

Spread

0.73

Spread (%)

0.6053 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Monday

13:31 - 19:59

Tuesday

13:31-19:59

Wednesday

13:31-19:59

Thursday

13:31-19:59

Friday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

149815017472

Shares Outstanding

1240806916

Earnings Date (Next)

2013-01-28

Div Yield

2025-09-29

Ex-Dividend Date

2025-09-15

Forward annual dividend rate

3.16

Forward annual dividend yield

0.0262

EPS

5.03

Learn more about this instrument

Gilead Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Related Instruments

Asset
Sell
Buy
Change (%)
View all instruments

Latest Education Articles

Show more
Ghko B 2025 Oct 23, 16:00

Trading Traps explained: How to identify and avoid a bull trap in trading

CFD Trading
Ghko B 2025 Oct 23, 16:00

Beginner's guide to day trading crypto: Best strategy for crypto day trading

Crypto
Ghko B 2025 Oct 23, 16:00

How to Start Bitcoin Trading: Top 10 Bitcoin Mining Apps for Android & iOS

Crypto
Trustpilot